HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells

Damodara Rao Mendu, Hermann Katinger, Joseph Sodroski, Kwang Sik Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein gp140 interacts with its specific receptors on the surface of the target cells leading to cellular activation through various signaling pathways. The effect of blocking the chemokine repertoire in human brain microvascular endothelial cells in HIV dementia (HAD) disease has not been reported. Characterizing the nature of HIV-1 envelope protein gp140 (T-tropic, HXBc2) receptor binding conditions to HBMEC is critical to gain insight into the HIV dementia, and eventually to rationally design the agents to block envelope protein receptor interactions. HIV-1 gp140 oligomers were purified and separated to monomers, dimers, and trimers. The binding conditions of gp140 to HBMEC chemokine receptor, CXCR4, were optimized with an aim of understanding the structural interactions in HAD. Analysis of the interaction between HIV-1 gp140 and CXCR4 of HBMEC by saturation binding, cross-competition analysis with radiolabeled SDF and gp140, revealed a strong interaction, specificity between HIV-1 gp140 and CXCR4. Our binding data demonstrate that HIV-1 envelope protein gp140 enters cells by protein receptor mediated interactions that are regulated by the conformational state of the gp140 at physiological environment (pH and temperature). The CXCR4 antibody 12G5 inhibited SDF-1 binding to HBMEC indicating the specificity of gp140 binding to HBMEC. Scatchard analysis revealed the presence of approximately 70250 gp140 binding sites per cell with a Kd of 4.5 nM. Cross-competition experiments using labeled SDF-1 and gp140 revealed that both unlabeled SDF-1 and gp140 are capable of displacing their radiolabeled counterparts. The binding assay conditions and radioligand binding assay are highly valuable to identify and design better HIV inhibitors for HAD.

Original languageEnglish (US)
Pages (from-to)466-471
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume363
Issue number3
DOIs
StatePublished - Nov 23 2007
Externally publishedYes

Fingerprint

Human Immunodeficiency Virus env Gene Products
Endothelial cells
Protein Binding
HIV-1
Brain
Endothelial Cells
Viruses
AIDS Dementia Complex
Assays
GP 140
Tropics
Chemokine Receptors
Radioligand Assay
Chemokines
Oligomers
Dimers

Keywords

  • Brain microvascular endothelial cells
  • HIV-1 envelope protein
  • Homologous competition binding studies
  • Optimal binding conditions

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. / Mendu, Damodara Rao; Katinger, Hermann; Sodroski, Joseph; Kim, Kwang Sik.

In: Biochemical and Biophysical Research Communications, Vol. 363, No. 3, 23.11.2007, p. 466-471.

Research output: Contribution to journalArticle

Mendu, Damodara Rao ; Katinger, Hermann ; Sodroski, Joseph ; Kim, Kwang Sik. / HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells. In: Biochemical and Biophysical Research Communications. 2007 ; Vol. 363, No. 3. pp. 466-471.
@article{6c92a4b413b9438b9d01cbe04111f219,
title = "HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells",
abstract = "Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein gp140 interacts with its specific receptors on the surface of the target cells leading to cellular activation through various signaling pathways. The effect of blocking the chemokine repertoire in human brain microvascular endothelial cells in HIV dementia (HAD) disease has not been reported. Characterizing the nature of HIV-1 envelope protein gp140 (T-tropic, HXBc2) receptor binding conditions to HBMEC is critical to gain insight into the HIV dementia, and eventually to rationally design the agents to block envelope protein receptor interactions. HIV-1 gp140 oligomers were purified and separated to monomers, dimers, and trimers. The binding conditions of gp140 to HBMEC chemokine receptor, CXCR4, were optimized with an aim of understanding the structural interactions in HAD. Analysis of the interaction between HIV-1 gp140 and CXCR4 of HBMEC by saturation binding, cross-competition analysis with radiolabeled SDF and gp140, revealed a strong interaction, specificity between HIV-1 gp140 and CXCR4. Our binding data demonstrate that HIV-1 envelope protein gp140 enters cells by protein receptor mediated interactions that are regulated by the conformational state of the gp140 at physiological environment (pH and temperature). The CXCR4 antibody 12G5 inhibited SDF-1 binding to HBMEC indicating the specificity of gp140 binding to HBMEC. Scatchard analysis revealed the presence of approximately 70250 gp140 binding sites per cell with a Kd of 4.5 nM. Cross-competition experiments using labeled SDF-1 and gp140 revealed that both unlabeled SDF-1 and gp140 are capable of displacing their radiolabeled counterparts. The binding assay conditions and radioligand binding assay are highly valuable to identify and design better HIV inhibitors for HAD.",
keywords = "Brain microvascular endothelial cells, HIV-1 envelope protein, Homologous competition binding studies, Optimal binding conditions",
author = "Mendu, {Damodara Rao} and Hermann Katinger and Joseph Sodroski and Kim, {Kwang Sik}",
year = "2007",
month = "11",
day = "23",
doi = "10.1016/j.bbrc.2007.08.121",
language = "English (US)",
volume = "363",
pages = "466--471",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - HIV-1 envelope protein gp140 binding studies to human brain microvascular endothelial cells

AU - Mendu, Damodara Rao

AU - Katinger, Hermann

AU - Sodroski, Joseph

AU - Kim, Kwang Sik

PY - 2007/11/23

Y1 - 2007/11/23

N2 - Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein gp140 interacts with its specific receptors on the surface of the target cells leading to cellular activation through various signaling pathways. The effect of blocking the chemokine repertoire in human brain microvascular endothelial cells in HIV dementia (HAD) disease has not been reported. Characterizing the nature of HIV-1 envelope protein gp140 (T-tropic, HXBc2) receptor binding conditions to HBMEC is critical to gain insight into the HIV dementia, and eventually to rationally design the agents to block envelope protein receptor interactions. HIV-1 gp140 oligomers were purified and separated to monomers, dimers, and trimers. The binding conditions of gp140 to HBMEC chemokine receptor, CXCR4, were optimized with an aim of understanding the structural interactions in HAD. Analysis of the interaction between HIV-1 gp140 and CXCR4 of HBMEC by saturation binding, cross-competition analysis with radiolabeled SDF and gp140, revealed a strong interaction, specificity between HIV-1 gp140 and CXCR4. Our binding data demonstrate that HIV-1 envelope protein gp140 enters cells by protein receptor mediated interactions that are regulated by the conformational state of the gp140 at physiological environment (pH and temperature). The CXCR4 antibody 12G5 inhibited SDF-1 binding to HBMEC indicating the specificity of gp140 binding to HBMEC. Scatchard analysis revealed the presence of approximately 70250 gp140 binding sites per cell with a Kd of 4.5 nM. Cross-competition experiments using labeled SDF-1 and gp140 revealed that both unlabeled SDF-1 and gp140 are capable of displacing their radiolabeled counterparts. The binding assay conditions and radioligand binding assay are highly valuable to identify and design better HIV inhibitors for HAD.

AB - Human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein gp140 interacts with its specific receptors on the surface of the target cells leading to cellular activation through various signaling pathways. The effect of blocking the chemokine repertoire in human brain microvascular endothelial cells in HIV dementia (HAD) disease has not been reported. Characterizing the nature of HIV-1 envelope protein gp140 (T-tropic, HXBc2) receptor binding conditions to HBMEC is critical to gain insight into the HIV dementia, and eventually to rationally design the agents to block envelope protein receptor interactions. HIV-1 gp140 oligomers were purified and separated to monomers, dimers, and trimers. The binding conditions of gp140 to HBMEC chemokine receptor, CXCR4, were optimized with an aim of understanding the structural interactions in HAD. Analysis of the interaction between HIV-1 gp140 and CXCR4 of HBMEC by saturation binding, cross-competition analysis with radiolabeled SDF and gp140, revealed a strong interaction, specificity between HIV-1 gp140 and CXCR4. Our binding data demonstrate that HIV-1 envelope protein gp140 enters cells by protein receptor mediated interactions that are regulated by the conformational state of the gp140 at physiological environment (pH and temperature). The CXCR4 antibody 12G5 inhibited SDF-1 binding to HBMEC indicating the specificity of gp140 binding to HBMEC. Scatchard analysis revealed the presence of approximately 70250 gp140 binding sites per cell with a Kd of 4.5 nM. Cross-competition experiments using labeled SDF-1 and gp140 revealed that both unlabeled SDF-1 and gp140 are capable of displacing their radiolabeled counterparts. The binding assay conditions and radioligand binding assay are highly valuable to identify and design better HIV inhibitors for HAD.

KW - Brain microvascular endothelial cells

KW - HIV-1 envelope protein

KW - Homologous competition binding studies

KW - Optimal binding conditions

UR - http://www.scopus.com/inward/record.url?scp=34948865244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948865244&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2007.08.121

DO - 10.1016/j.bbrc.2007.08.121

M3 - Article

VL - 363

SP - 466

EP - 471

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -